(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s ty ...

(“Alpha”) of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets ) (“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is ...

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is ...

At the end of this year, we understand different risk factors for dementia and potential treatments more deeply than ever before. Researchers working on the Lancet Commission study, part-funded by ...

How Dementia Affects the ... of Huntington's disease (HD), according to a new ... 'Alzheimer's in Dish' Model Shows Promise for Accelerating Drug Discovery Nov. 27, 2024 — A decade ago ...

Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...